Brief: Axcella Announces Initiation Of EMMPACTSM Phase 2B Clinical Trial Of AXA1125
11/05/2021 13:48
May 11 (Reuters) - Axcella Health Inc AXLA.O :
* AXCELLA ANNOUNCES INITIATION OF EMMPACTSM PHASE 2B
CLINICAL
TRIAL OF AXA1125
* AXCELLA HEALTH INC - INITIAL CLINICAL SITES ACTIVATED AND
PATIENT SCREENING UNDERWAY
* AXCELLA HEALTH INC - POTENTIAL FOR AXA1125 TO SERVE AS A
FIRST-LINE THERAPY FOR PATIENTS WITH NONALCOHOLIC
STEATOHEPATITIS
Source text for Eikon: ID:nBwbXDs7ma
Further company coverage: AXLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Axcella Health
See all newsAxcella Health Inc expected to post a loss of $1.25 a share - Earnings Preview
Brief: Axcella Health Inc- On Oct 4, Co Received Notice From Nasdaq That Co Had Regained Compliance With Nasdaq
Brief: Axcella Announces Reverse Stock Split Effective September 19, 2023
U.S. STOCKS ON THE MOVE-PDD Holdings, Catalent, Best Buy
Brief: Axcella Granted Patent For Long Covid Fatigue Treatment